164 related articles for article (PubMed ID: 36857819)
21. Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
Thomas HMT; Hippe DS; Forouzannezhad P; Sasidharan BK; Kinahan PE; Miyaoka RS; Vesselle HJ; Rengan R; Zeng J; Bowen SR
Discov Oncol; 2022 Sep; 13(1):85. PubMed ID: 36048266
[TBL] [Abstract][Full Text] [Related]
22. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
23. Radiomic prediction of radiation pneumonitis on pretreatment planning computed tomography images prior to lung cancer stereotactic body radiation therapy.
Hirose TA; Arimura H; Ninomiya K; Yoshitake T; Fukunaga JI; Shioyama Y
Sci Rep; 2020 Nov; 10(1):20424. PubMed ID: 33235324
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
[TBL] [Abstract][Full Text] [Related]
25. Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment.
Wang C; Zhu H; Huang H; Sun Z; Teng Y; Li Y
Future Oncol; 2023 Jan; 19(3):259-270. PubMed ID: 36891950
[TBL] [Abstract][Full Text] [Related]
26. Discrimination of mediastinal metastatic lymph nodes in NSCLC based on radiomic features in different phases of CT imaging.
Sha X; Gong G; Qiu Q; Duan J; Li D; Yin Y
BMC Med Imaging; 2020 Feb; 20(1):12. PubMed ID: 32024469
[TBL] [Abstract][Full Text] [Related]
27. Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.
Kraus KM; Oreshko M; Schnabel JA; Bernhardt D; Combs SE; Peeken JC
Lung Cancer; 2024 Mar; 189():107507. PubMed ID: 38394745
[TBL] [Abstract][Full Text] [Related]
28. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
[TBL] [Abstract][Full Text] [Related]
29. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
Xu H; Feng H; Zhang W; Wei F; Zhou L; Liu L; Zhao Y; Lv Y; Shi X; Zhang J; Ren X
Exp Cell Res; 2022 Jul; 416(1):113157. PubMed ID: 35427598
[TBL] [Abstract][Full Text] [Related]
30. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
[TBL] [Abstract][Full Text] [Related]
31. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
32. Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
Cong M; Feng H; Ren JL; Xu Q; Cong L; Hou Z; Wang YY; Shi G
Lung Cancer; 2020 Jan; 139():73-79. PubMed ID: 31743889
[TBL] [Abstract][Full Text] [Related]
33. Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitis.
Hindocha S; Hunter B; Linton-Reid K; George Charlton T; Chen M; Logan A; Ahmed M; Locke I; Sharma B; Doran S; Orton M; Bunce C; Power D; Ahmad S; Chan K; Ng P; Toshner R; Yasar B; Conibear J; Murphy R; Newsom-Davis T; Goodley P; Evison M; Yousaf N; Bitar G; McDonald F; Blackledge M; Aboagye E; Lee R
Radiother Oncol; 2024 Jun; 195():110266. PubMed ID: 38582181
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
Watanabe S; Ota T; Hayashi M; Ishikawa H; Otsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Miyabayashi T; Miura S; Tanaka H; Abe T; Okajima M; Terada M; Ishida T; Iwashima A; Sato K; Yoshizawa H; Kikuchi T
Cancer Med; 2020 May; 9(9):3070-3077. PubMed ID: 32150668
[TBL] [Abstract][Full Text] [Related]
35. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Tunali I; Gray JE; Qi J; Abdalah M; Jeong DK; Guvenis A; Gillies RJ; Schabath MB
Lung Cancer; 2019 Mar; 129():75-79. PubMed ID: 30797495
[TBL] [Abstract][Full Text] [Related]
36. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
37. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
38. Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study.
Yang S; Huang S; Ye X; Xiong K; Zeng B; Shi Y
BMC Pulm Med; 2022 Nov; 22(1):402. PubMed ID: 36344945
[TBL] [Abstract][Full Text] [Related]
39. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.
Zhu X; Dong D; Chen Z; Fang M; Zhang L; Song J; Yu D; Zang Y; Liu Z; Shi J; Tian J
Eur Radiol; 2018 Jul; 28(7):2772-2778. PubMed ID: 29450713
[TBL] [Abstract][Full Text] [Related]
40. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
